TD Cowen analyst Joseph Thome maintained a Hold rating on PTC Therapeutics (PTCT – Research Report) today and set a price target of $50.00. The ...

Investors and market watchers will likely monitor PTC Therapeutics (NASDAQ:PTCT) closely to see if the company's performance aligns with Cowen's projections and to gauge the potential impact of this ...

Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has earned a consensus rating of “Hold” from the fifteen research ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

Equities research analysts at Cantor Fitzgerald increased their FY2024 earnings estimates for PTC Therapeutics in a report ...

Shares of PTC Therapeutics Inc. climbed nearly 1% pre-market Tuesday, poised to extend their rally to levels last seen in April 2023. The stock’s momentum follows the company’s $1 billion ...

CARGO Therapeutics, Inc. (CRGX – Research Report) received a Hold rating and price target from William Blair analyst Sami Corwin today. The ...

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program PTC Therapeutics partners with Novartis for its PTC518 Huntington's program in a deal valued up ...

WARREN, N.J. - PTC Therapeutics, Inc. (NASDAQ: NASDAQ:PTCT), a biopharmaceutical company with a market capitalization of $3.4 billion and an impressive 60.8% stock return over... ByInvesting.com ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at ...

PTC Therapeutics has demonstrated strong financial performance in recent quarters, consistently beating revenue expectations. In the third quarter of 2024, the company reported a total revenue beat of ...